Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Date:4/21/2009

>

Of 18 evaluable patients who received the every-four-week FOLPI regimen, 67 percent achieved disease control (partial response and stable disease). Of 55 evaluable patients who received the every-two-week FOLPI regimen, 75 percent achieved disease control.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

In addition to the Phase 2 clinical trial in CRC, Poniard is currently evaluating the efficacy and safety of picoplatin in small cell lung cancer in a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The Company reached its enrollment target in this international, multi-center, randomized, controlled trial in March 2009. Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with castration-resistant (or hormone-refractory) prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information p
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
2. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
3. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
4. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
5. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
8. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
9. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
10. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
11. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Texas Fertility Center (TFC) announces the opening ... a Central Texas footprint that includes Round Rock, Central ... for the region’s most established practice will provide full ... Buda, Kyle and San Marcos communities. , “We ... to individuals and couples living in and around South ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 Marktech ... of deep ultra violet emitters in the 280 nm ... standard UV emitters which range from 280nm to 405nm. ... and water sanitation as well as curing. Mark Campito, ... line of special interest to manufacturers is that we ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 Dr. ... my third book on healthcare offers a three phase ... 21st century healthcare delivery system that would go far ... state’s responsibility regarding the delivery of healthcare.” , “Every ... safety has failed to provide discernable progress throughout that ...
(Date:9/23/2014)... 2014 Healthcare professionals, patients ... convene at the Society for Integrative Oncology ... October 26-28 in Houston, Texas to discuss ... in individualized integrative cancer care. This multi-disciplinary ... nutritionists, naturopaths, acupuncturists, and other complementary care ...
Breaking Biology Technology:Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3Marktech Introduces its New Line of Deep UV Emitters 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3
... (NYSE: SPW ) today announced that it ... leading engineering company supplying processing solutions for the food ... New Zealand. Terms of the acquisition were not disclosed. ... in the New Zealand dairy, beverage and bio-tech markets, ...
... advisory committee recommended today that the Food and Drug ... US as a once-daily long-term maintenance bronchodilator treatment of ... (COPD), including chronic bronchitis and/or emphysema. ... recommending approval of the 75 mcg dose. The advisory ...
... In addition to reliable high efficiency transfection reagents, ... development of the Reagent Agent(SM) - a new online ... of any nucleic acid into any cell type, including ... based on extensive in-house transfection and electroporation data, customer ...
Cached Biology Technology:SPX Announces Acquisition of B.W. Murdoch Ltd, Broadening Process Engineering and Project Management Capabilities in New Zealand and the Asia Pacific Region 2FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD 2FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD 3FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD 4Reagent Agent(SM) Transfection Cell Line Database From The Transfection Experts 2
(Date:9/22/2014)... have shown that after a long stay in the ... microbe species remain behind in patients, intestines. The team ... become deadly when provoked by conditions that mimic the ... in mBio , the online open-access journal of ... monitoring and treatment of ICU patients who can develop ...
(Date:9/22/2014)... ATLANTA September 23, 2014 A new American ... Supplemental Nutrition Assistance Program (SNAP), previously known as ... scores compared with income eligible non-participants. The authors ... programs aimed at enhancing the dietary quality of ... assist low-income individuals and households with the resources ...
(Date:9/22/2014)... species have vanished from tropical islands because of ... discovered how fossils can be used to restore ... organic materials found in fossil bones, which contain ... a new study available online and in the ... . Pre-human island ecosystems provide vital clues for ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Federal food program puts food on the table, but dietary quality could be improved 2Answer to restoring lost island biodiversity found in fossils 2
... edible crops for biofuels poses a dilemma: Is it ... of an already malnourished population? David Pimentel and his ... problems linked to converting a variety of crops into ... are also economically and environmentally costly and nowhere near ...
... 28, 2009 Mice with increased levels of a natural ... researchers at UT Southwestern Medical Center have found. ... the "weight-loss hormone," leptin, the researchers report. Finding ... as a therapy against obesity, said Dr. Masashi Yanagisawa, professor ...
... 27, 2009 Scientists and engineers will face a ... clean water to millions of people caught up in ... engineers said today at a briefing at the Broadcast ... Report on the American Chemical Society,s Global Challenges/Chemistry Solutions. ...
Cached Biology News:Biofuels ignite food crisis debate 2Natural brain substance blocks weight gain in mice, UT Southwestern researchers discover 2Substantial work ahead for water issues, say scientists at ACS' Final Report briefing 2Substantial work ahead for water issues, say scientists at ACS' Final Report briefing 3
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
CD45/CD34 combination 50 tests...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: